Meningococcal Disease and Quadrivalent MenACWY-CRM Vaccine (Menveo®)
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Meningococcal Disease, manifesting as meningitis and septicemia, is a life-threatening bacterial infection that results in significant morbidity and mortality, particularly in childhood. Its epidemic potential and limited opportunities for clinical intervention due to its rapid course present unique public health and clinical challenges. Incidence is highest in infants and young children, with a secondary peak of risk in adolescents. Approximately 10% of cases are fatal and survivors can be left with serious and permanent sequelae including amputations, hearing loss and cognitive impairment. Transmission is only from human-to-human, by infected respiratory tract secretions or saliva and therefore crowding poses a tremendously elevated risk for disease development. Military recruits and university students are at high risk due to the high carriage rate in adolescents, their behavior patterns and close contact. Menveo® (Novartis Vaccines and Diagnostics), a novel quadrivalent meningococcal conjugate vaccine directed against meningococcal serogroups A, C, W-135 and Y, has been shown to be immunogenic and well tolerated in all age groups and was recently licensed for use in Korea. Recent cases and deaths among military recruits drew public attention to their elevated risk and the Korean government has recommended vaccination of all new military recruits. Many Korean students seek to attend school, university, or language institutes in countries where routine meningococcal vaccination is required - clinicians should be aware of such requirements to ensure that students are vaccinated prior to arrival in the destination country.
Abstract
Meningococcal Disease, manifesting as meningitis and septicemia, is a life-threatening bacterial infection that results in significant morbidity and mortality, particularly in childhood. Its epidemic potential and limited opportunities for clinical intervention due to its rapid course present unique public health and clinical challenges. Incidence is highest in infants and young children, with a secondary peak of risk in adolescents. Approximately 10% of cases are fatal and survivors can be left with serious and permanent sequelae including amputations, hearing loss and cognitive impairment. Transmission is only from human-to-human, by infected respiratory tract secretions or saliva and therefore crowding poses a tremendously elevated risk for disease development. Military recruits and university students are at high risk due to the high carriage rate in adolescents, their behavior patterns and close contact. Menveo® (Novartis Vaccines and Diagnostics), a novel quadrivalent meningococcal conjugate vaccine directed against meningococcal serogroups A, C, W-135 and Y, has been shown to be immunogenic and well tolerated in all age groups and was recently licensed for use in Korea. Recent cases and deaths among military recruits drew public attention to their elevated risk and the Korean government has recommended vaccination of all new military recruits. Many Korean students seek to attend school, university, or language institutes in countries where routine meningococcal vaccination is required - clinicians should be aware of such requirements to ensure that students are vaccinated prior to arrival in the destination country.
참고문헌 (70)
- McIntyre PB, "Effect of vaccines on bacterial meningitis worldwide", Lancet, 380, pp.1703~1711 (2012)
- Stephens DS, "Epidemic meningitis, meningococcemia, and Neisseria meningitidis", Lancet, 369, pp.2196~2210 (2007)
- Centers for Disease Control and Prevention, "Outbreak of meningococcal disease associated with an elementary school -- Oklahoma, March 2010", MMWR Morb Mortal Wkly Rep, 61, pp.217~221 (2012)
- Krause G, "Mass vaccination campaign following community outbreak of meningococcal disease", Emerg Infect Dis, 8, pp.1398~1403 (2002)
- Nolan P, "The Rhode Island meningitis vaccine experience--mass vaccination campaigns, politics and health policy", Med Health R I, 87, pp.65~67 (2004)
- Thompson MJ, "Clinical recognition of meningococcal disease in children and adolescents", Lancet, 367, pp.397~403 (2006)
- Fitzwater SP, "Haemophilus influenzae type b conjugate vaccines: considerations for vaccination schedules and implications for developing countries", Hum Vaccin, 6, pp.810~818 (2010)
- Tan TQ, "Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines", Clin Microbiol Rev, 25, pp.409~419 (2012)
- Yazdankhah SP, "Neisseria meningitidis: an overview of the carriage state", J Med Microbiol, 53, pp.821~832 (2004)
- van Deuren M, "Update on meningococcal disease with emphasis on pathogenesis and clinical management", Clin Microbiol Rev, 13, pp.144~166 (2000)
- Davila S, "Genome-wide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease", Nat Genet, 42, pp.772~776 (2010)
- Owen EP, "Complement ü component C5 and C6 mutation screening indicated in meningococcal disease in South Africa", S Afr Med J, 102, pp.525~527 (2012)
- Helminen M, "A novel mutation W388X underlying properdin deficiency in a Finnish family", Scand J Immunol, 75, pp.445~448 (2012)
- Ram S, "Infections of people with complement deficiencies and patients who have undergone splenectomy", Clin Microbiol Rev, 23, pp.740~780 (2010)
- Hermans PW, "Plasminogen activator inhibitor type 1 gene polymorphism and sepsis", Clin Infect Dis, 41, pp.453~458 (2005)
- Bradley DT, "Genetic susceptibility to invasive meningococcal disease: MBL2 structural polymorphisms revisited in a large case-control study and a systematic review", Int J Immunogenet, 39, pp.328~337 (2012)
- Girard MP, "A review of vaccine research and development: meningococcal disease", Vaccine, 24, pp.4692~4700 (2006)
- Erickson L, "Complications and sequelae of meningococcal disease in Quebec, Canada, 1990-1994", Clin Infect Dis, 26, pp.1159~1164 (1998)
- Viner RM, "Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study", Lancet Neurol, 11, pp.774~783 (2012)
- van de Beek D, "Advances in treatment of bacterial meningitis", Lancet, 380, pp.1693~1702 (2012)
- 조상래, "Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study", LANCET, 380(9851), pp.1406~1417, ELSEVIER SCIENCE inC
- World Health Organization, "Meningococcal vaccines: WHO position paper", Wkly Epidemiol Rec, 86, pp.521~539 (2011)
- Agrawal S, "Acute bacterial meningitis in infants and children. epidemiology and management", Paediatr Drugs, 13, pp.385~400 (2011)
- Goldschneider I, "Human immunity to the meningococcus. I. The role of humoral antibodies", J Exp Med, 129, pp.1307~1326 (1969)
- Harrison LH, "Invasive meningococcal disease in adolescents and young adults", JAMA, 286, pp.694~699 (2001)
- Halperin SA, "The changing and dynamic epidemiology of meningococcal disease", Vaccine, 30(2), pp.26~36 (2012)
- Harrison LH, "Global epidemiology of meningococcal disease", Vaccine, 27(2), pp.51~63 (2009)
- du Plessis M, "Population snapshot of invasive serogroup B meningococci in South Africa from 2005 to 2008", J Clin Microbiol, 50, pp.2577~2584 (2012)
- Pollard AJ, "Global epidemiology of meningococcal disease and vaccine efficacy", Pediatr Infect Dis J, 23, pp.274~279 (2004)
- Bröker M, "Meningococcal serogroup Y emergence in Europe: Update 2011", Hum Vaccin Immunother, 8 (2012)
- Vyse A, "Meningococcal disease in Asia: an under-recognized public health burden", Epidemiol Infect, 139, pp.967~985 (2011)
- Kilic A, "Clonal Spread of Serogroup W135 Meningococcal Disease in Turkey", J Clin Microbiol, 44, pp.222~224 (2006)
- Kriz P, "Changing epidemiology of meningococcal disease in Europe from the mid-20th to the early 21st century", Expert Rev Vaccines, 10, pp.1477~1486 (2011)
- 조혜경, "The Causative Organisms of Bacterial Meningitis in Korean Children in 1996-2005", Journal of Korean Medical Science, 25(6), pp.895~899 (2010), 대한의학회
- Kim SA, "expanded age range for meningococcal meningitis: molecular diagnostic evidence from population-based surveillance in Asia", BMC Infect Dis, 12, pp.310~ (2012)
- Sang-OhLee, "Meningococcal Disease in the Republic of Korea Army: Incidence and Serogroups Determined by PCR", Journal of Korean Medical Science, 18(2), pp.163~166 (2003), 대한의학회
- Park HS, "Carrier rate, serogroup and vaccination effect of Neisseria meningitidis on army trainees in Korea", Chungbuk Med J, 5, pp.45~57 (1995)
- Holers VM, "The spectrum of complement alternative pathway-mediated diseases", Immunol Rev, 223, pp.300~316 (2008)
- Zuber J, "Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies", Nat Rev Nephrol, 8, pp.643~657 (2012)
- Békondi C, "Primary and opportunistic pathogens associated with meningitis in adults in Bangui, Central African Republic, in relation to human immunodeficiency virus serostatus", Int J Infect Dis, 10, pp.387~395 (2006)
- Bruce MG, "Risk factors for meningococcal disease in college students", JAMA, 286, pp.688~693 (2001)
- Brundage JF, "Meningococcal disease among United States military service members in relation to routine uses of vaccines with different serogroup-specific components, 1964- 1998", Clin Infect Dis, 35, pp.1376~1381 (2002)
- MacLennan J, "Social behavior and meningococcal carriage in British teenagers", Emerg Infect Dis, 12, pp.950~957 (2006)
- Dull PM, "Meningococcal vaccine development- from glycoconjugates against MenACWY to proteinsagainst MenB - potential for broad protection againstmeningococcal disease", Vaccine, 30(2), pp.18~25 (2012)
- Lee LH, "Effect of increased CRM197 carrier protein dose on meningococcal C bactericidal antibody response", Clin Vaccine Immunol, 19, pp.551~556 (2012)
- Andrews N, "Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England", Clin Diagn Lab Immunol, 10, pp.780~786 (2003)
- Campbell H, "Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity", Clin Vaccine Immunol, 17, pp.840~847 (2010)
- De Wals P, "Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec", Pediatr Infect Dis J, 30, pp.566~569 (2011)
- Macneil JR, "Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine", Pediatr Infect Dis J, 30, pp.451~455 (2011)
- Novak RT, "Ouédraogo-Traoré R, Sangaré L, et al. Serogroup A meningococcal conjugate accination in Burkina Faso: analysis of national surveillance data", Lancet Infect Dis, 12, pp.757~764 (2012)
- Centers for Disease Control and Prevention, "Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use - Advisory Committee on Immunization Practices (ACIP)", MMWR Morb Mortal Wkly Rep, 59, pp.273~ (2010)
- Klein NP, "Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants", Pediatr Infect Dis J, 31, pp.64~71 (2012)
- Klein NP, "Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine administered concomitantly with measles, mumps, rubella, varicella vaccine in healthy toddlers", Vaccine, 30, pp.3929~3936 (2012)
- Black S, "Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2-10 years of age", Vaccine, 28, pp.657~663 (2010)
- Halperin SA, "Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age", Vaccine, 28, pp.7865~7872 (2010)
- Jackson LA, "Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents", Clin Infect Dis, 49, pp.1~10 (2009)
- Jackson LA, "A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents", Pediatr Infect Dis J, 28, pp.86~91 (2009)
- Reisinger KS, "Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra", Clin Vaccine Immunol, 16, pp.1810~1815 (2009)
- Gill CJ, "Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents", Hum Vaccin, 6, pp.881~887 (2010)
- Jackson LA, "Persistence of bactericidal antibodies and boosting after vaccination with Menveo® in adolescents enrolled in phase II and III clinical studies", Presented at 49th annual meeting of IDSA (2011)
- Jacobson RM, "Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents", Pediatr Infect Dis J (2012)
- Gasparini R, "Randomized trial on the safety, tolerability, and immunogenicity of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis vaccine in adolescents and young adults", Clin Vaccine Immunol, 17, pp.537~544 (2010)
- Arguedas A, "Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines", Vaccine, 28, pp.3171~3179 (2010)
- Pina ML, "Safety and immunogenicity of a quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in infants and toddlers: three multicenter phase 3 studies", Pediatr Infect Dis J, 31, pp.1173~1183 (2012)
- Lee HJ, "Safety and immunogenicity of MenACWYCRM vaccine administered to Korean adolescents and adults", Presented at 19th WONCA Asia Pacific Regional Conference (2012)
- NATO Standardization Agency, "National military strategies for vaccination of NATO forces", ~ (2008)
- "Saudi Ministry of Health Requirements"[URL]
- "Korean Educational Development Institute"[URL]
- "Discover the NMA’s Work State by State"[URL]
- "Higher Education in Korea"[URL]